Showing 141-160 of 746 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Benzodiazepines and related drugs for insomnia in palliative care
Cochrane Systematic Reviews, 22-Nov-2013
Insomnia, a subjective complaint of poor sleep and associated impairment in daytime function, is a common problem. Currently, benzodiazepines are the most used pharmacological treatment for this complaint. They are considered helpful for occasional short-
- Benzodiazepines for alcohol withdrawal
Cochrane Systematic Reviews, 17-Mar-2010
Alcohol abuse and dependence represents a serious health problem worldwide with social, interpersonal and legal interpolations. Benzodiazepines have been widely used for the treatment of alcohol withdrawal symptoms. Moreover it is unknown whether differen
- Benzodiazepines for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 20-Jan-2018
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychoti
- Benzodiazepines for neuroleptic‐induced acute akathisia
Cochrane Systematic Reviews, 25-Oct-1999
Neuroleptic-induced akathisia is one of the most common and distressing early-onset adverse effects of antipsychotic drugs, being associated with poor compliance with treatment, and thus, ultimately, to an increase risk of relapse. This review assesses th
- Benzodiazepines for psychosis‐induced aggression or agitation
Cochrane Systematic Reviews, 8-Dec-2017
Acute psychotic illness, especially when associated with agitated or violent behaviour, can require urgent pharmacological tranquillisation or sedation. In several countries, clinicians often use benzodiazepines (either alone or in combination with antips
- Benzodiazepines for schizophrenia
Cochrane Systematic Reviews, 14-Nov-2012
Because of the high number of people with schizophrenia not responding adequately to monotherapy with antipsychotic agents, the evidence regarding the efficacy and safety of additional medication was examined in a number of clinical trials. One approach t
- Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis
Cochrane Systematic Reviews, 7-Jan-2014
Optimal antibiotic treatment for sepsis is imperative. Combining a beta lactam antibiotic with an aminoglycoside antibiotic may provide certain advantages over beta lactam monotherapy.
- Beta-blocker supplementation of standard drug treatment for schizophrenia
Cochrane Systematic Reviews, 15-Jun-2010
Many people with schizophrenia or similar severe mental disorders do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, amongst them beta-adrenergic receptor antag
- Beta‐blocker therapy for tremor in Parkinson's disease
Cochrane Systematic Reviews, 20-Jan-2003
The tremor of Parkinson's disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as
- Beta‐blockers for hypertension
Cochrane Systematic Reviews, 20-Jan-2017
Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardia
- Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia
Cochrane Systematic Reviews, 21-Sep-2016
Continued controversy surrounds the optimal empirical treatment for febrile neutropenia. New broad-spectrum beta-lactams have been introduced as single treatment, and classically, a combination of a beta-lactam with an aminoglycoside has been used.
- Bisphosphonate therapy for children and adolescents with secondary osteoporosis
Cochrane Systematic Reviews, 24-May-2010
Children with chronic illnesses are at increased risk for reductions in bone strength and subsequent fractures (osteoporosis), either due to the impact of the underlying condition on skeletal development or due to the osteotoxic effect of medications (e.g
- Bisphosphonates and other bone agents for breast cancer
Cochrane Systematic Reviews, 30-Oct-2017
Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied
- Bisphosphonates for advanced prostate cancer
Cochrane Systematic Reviews, 26-Dec-2017
The prevalence and incidence of pain and skeletal complications of metastatic bone disease such as pathologic fractures, spinal cord compression and hypercalcemia is high and an important contributor to morbidity, poor performance status and decreased qua
- Bisphosphonates for osteoporosis in people with cystic fibrosis
Cochrane Systematic Reviews, 13-Mar-2014
Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. Bisphosphonates can increase bone mineral density and decrease the risk of new fractures in post-menopausal women and people receiving long-term or
- Bisphosphonates for steroid‐induced osteoporosis
Cochrane Systematic Reviews, 5-Oct-2016
This is an update of a Cochrane Review first published in 1999. Corticosteroids are widely used in inflammatory conditions as an immunosuppressive agent. Bone loss is a serious side effect of this therapy. Several studies have examined the use of bisphosp
- Bisphosphonates for the relief of pain secondary to bone metastases
Cochrane Systematic Reviews, 22-Apr-2002
Bisphosphonates form part of standard therapy for hypercalcemia and the prevention of skeletal events in some cancers. However, the role of bisphosphonates in pain relief for bony metastases remains uncertain.
- Bisphosphonates in multiple myeloma: an updated network meta‐analysis
Cochrane Systematic Reviews, 18-Dec-2017
Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overal
- Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)
Cochrane Systematic Reviews, 20-Jan-2010
Cerebral palsy (CP) is "a group of permanent disorders of the development of movement and posture causing activity limitation(s) that are attributed to non-progressive disturbance that occurred in the developing fetal or infant brain" (Rosenbaum 2007, p.9
- Botulinum toxin injections for adults with overactive bladder syndrome
Cochrane Systematic Reviews, 9-Nov-2011
Overactive bladder syndrome (OAB) is a common condition with a significant negative impact on quality of life characterised by urgency with or without urge incontinence, frequency and nocturia. Intravesical botulinum toxin is being increasingly used to t
